Cochrane Abstracts
Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Immune Checkpoint Inhibitors Plus Platinum‐based Chemotherapy Compared to Platinum‐based Chemotherapy With or Without Bevacizumab for First‐line Treatment of Older People With Advanced Non‐small Cell Lung Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440657/0/Immune_checkpoint_inhibitors_plus_platinum‐based_chemotherapy_compared_to_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_first‐line_treatment_of_older_people_with_advanced_non‐small_cell_lung_cancer.
Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440657/0/Immune_checkpoint_inhibitors_plus_platinum‐based_chemotherapy_compared_to_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_first‐line_treatment_of_older_people_with_advanced_non‐small_cell_lung_cancer. Accessed December 14, 2024.
Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440657/0/Immune_checkpoint_inhibitors_plus_platinum‐based_chemotherapy_compared_to_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_first‐line_treatment_of_older_people_with_advanced_non‐small_cell_lung_cancer
Immune Checkpoint Inhibitors Plus Platinum‐based Chemotherapy Compared to Platinum‐based Chemotherapy With or Without Bevacizumab for First‐line Treatment of Older People With Advanced Non‐small Cell Lung Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 14]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440657/0/Immune_checkpoint_inhibitors_plus_platinum‐based_chemotherapy_compared_to_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_first‐line_treatment_of_older_people_with_advanced_non‐small_cell_lung_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer
ID - 440657
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440657/0/Immune_checkpoint_inhibitors_plus_platinum‐based_chemotherapy_compared_to_platinum‐based_chemotherapy_with_or_without_bevacizumab_for_first‐line_treatment_of_older_people_with_advanced_non‐small_cell_lung_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
